David R. Liu
David R. Liu | |
---|---|
E.J. Corey | |
Chinese name | |
Hanyu Pinyin | Liú Rúqiān |
Wade–Giles | Liu Ju-ch'ien |
David Ruchien Liu (born 1973) is an American molecular biologist and chemist. He is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator.[1]
Early life and education
Liu was born in Riverside, California on June 12, 1973.[2] Both his parents immigrated to the United States from Taiwan.[3] His father is an aerospace engineer; his mother is a retired physics professor at the University of California, Riverside.[2]
While in high school, Liu finished second in the 1990 national
Academic career
Liu graduated first in his class at Harvard in 1994.
Liu has earned several university-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship. Liu has published more than 225 papers and is the inventor of more than 90 issued U.S. patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the
Research
Liu's research group pioneered
His lab also developed phage-assisted continuous evolution (PACE),[17] a technique that uses the short 10-minute lifespan of M13 bacteriophage to achieve the rapid evolution of useful proteins. The lab has used PACE and its directed evolution efforts to generate new genome editing tools that allow for expanded DNA accessibility and DNA base conversions.[18] He has published over 230 peer-reviewed publications and his H-index is ≥130 according to Google Scholar.[19]
Commercial activity
Liu co-founded Editas Medicine (genome editing with CRISPR nucleases for human therapeutics), Pairwise Plants (genome editing for agriculture), Beam Therapeutics (base editing for human therapeutics), Exo Therapeutics (novel small-molecule drug discovery), Chroma Medicine (genomic medicines that harness epigenetics), Resonance Medicine (novel enzymatic solutions for unment challenges in medicine), and Nvelop Therapeutics (novel gene editing delivery technologies). He is the scientific founder of Prime Medicine (prime editing for human therapeutics).
Liu also founded Permeon Biologics and Ensemble Therapeutics. Permeon Biologics was founded in 2011 by Liu and
Personal life
He met his wife, Julie Liu, while attending U.C Berkeley.[22]
Selected papers
- Gartner, ZJ; Liu, DR (July 2001). "The generality of DNA-templated synthesis as a basis for evolving non-natural small molecules". J. Am. Chem. Soc. 123 (28): 6961–3. PMID 11448217.
- Kanan, MW; Rozenman, MM; Sakurai, K; Snyder, TM; Liu, DR (2004). "Reaction discovery enabled by DNA-templated synthesis and in vitro selection". Nature. 431 (7008): 545–9. PMID 15457254.
- Gartner, ZJ; Tse, BN; Grubina, R; Doyon, JB; Snyder, TM; Liu, DR (September 2004). "DNA-templated organic synthesis and selection of a library of macrocycles". Science. 305 (5690): 1601–5. PMID 15319493.
- Georghiou, G; Kleiner, RE; Pulkoski-Gross, M; Liu, DR; Seeliger, MA (2012). "Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles". Nature Chemical Biology. 8 (4): 366–74. PMID 22344177.
- Cronican, JJ; Thompson, DB; Beier, KT; McNaughton, BR; Cepko, CL; Liu, DR (2010). "Potent delivery of functional proteins into Mammalian cells in vitro and in vivo using a supercharged protein". ACS Chem. Biol. 5 (8): 747–52. PMID 20545362.
- Komor, AC; Kim, YB; Packer, MS; Zuris, JA; Liu, DR (19 May 2016). "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage". Nature. 533 (7603): 420–4. PMID 27096365.
- Kim, YB; Komor, AC; Levy, JM; Packer, MS; Zhao, KT; Liu, DR (April 2017). "Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions". Nature Biotechnology. 35 (4): 371–376. PMID 28191901.
- Gaudelli, NM; Komor, AC; Rees, HA; Packer, MS; Badran, AH; Bryson, DI; Liu, DR (23 November 2017). "Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage". Nature. 551 (7681): 464–471. PMID 29160308.
- Lawrence, M. S.; Phillips, K. J.; Liu, D. R. (2007). "Supercharging Proteins Can Impart Extraordinary Resilience". J. Am. Chem. Soc. 129 (33): 10110–10112. PMID 17665911.
- McNaughton, B. R.; Cronican, J. J.; Liu, D. R. (2009). "Mammalian Cell Penetration, siRNA Transfection, and DNA Transfection by Supercharged Proteins". Proc. Natl. Acad. Sci. USA. 106 (15): 6111–6116. PMID 19307578.
- Esvelt, K. M.; Carlson, J. C.; Liu, D. R. (2011). "A System for the Continuous Directed Evolution of Biomolecules". Nature. 472 (7344): 499–503. PMID 21478873.
- Dickinson, B. C.; Leconte, A. M.; Allen, B.; Esvelt, K. M.; Liu, D. R. (2013). "Experimental Interrogation of the Path Dependence and Stochasticity of Protein Evolution Using Phage-Assisted Continuous Evolution". Proc. Natl. Acad. Sci. USA. 110 (22): 9007–9012. PMID 23674678.
- Maianti, J. P.; McFedries, A.; Foda, Z. H.; Kleiner, R. E.; Du, X.-Q.; Leissring, M. A.; Tang, W.-J.; Charron, M. J.; Seeliger, M. A.; Saghatelian, A.; Liu, D. R. (2014). "Anti-Diabetic Activity of Insulin-Degrading Enzyme Inhibitors Mediated by Multiple Hormones". Nature. 511 (7507): 94–98. PMID 24847884.
- Zuris, J. A.; Thompson, D. B.; Shu, Y.; Guilinger, J. P.; Bessen, J. L.; Hu, J. H.; Maeder, M. L.; Joung, J. K.; Chen, Z.-Y.; Liu, D. R. (2015). "Cationic Lipid-Mediated Delivery of Proteins Enables Efficient Protein-Based Genome Editing In Vitro and In Vivo". Nat. Biotechnol. 33 (1): 73–80. PMID 25357182.
- Badran, A. H.; Guzov, V. M.; Huai, Q.; Kemp, M. M.; Vishwanath, P.; Kain, W.; Evdokimov, A.; Moshiri, F.; Turner, K. H.; Wang, P.; Malvar, T.; Liu, D. R. (2016). "Continuous Evolution of B. thuringiensis Toxins Overcomes Insect Resistance". Nature. 533 (7601): 58–63. PMID 27120167.
- Gao, X.; Lamas, V.; Huang, M.; Yeh, W.-H.; Pan, B.; Hu, Y.-J.; Hu, J. H.; Thompson, D. B.; Shu, Y.; Li, Y.; Wang, H.; Yang, S.; Xu, Q.; Polley, D. B.; Liberman, M. C.; Kong, W.-J.; Holt, J. R.; Chen, Z.-Y.; Liu, D. R. (2018). "Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents". Nature. 553 (7687): 217–221. PMID 29258297.
- Tang, W; Liu, D.R. (2018). "Rewritable multi-event analog recording in bacterial and mammalian cells". Science. 360 (6385): eaap8992. PMID 29449507.
- Hu, J. H.; Miller, S. M.; Geurts, M. H.; Tang, W.; Chen, L.; Sun, N.; Zeina, C.; Gao, X.; Rees, H. A.; Lin, Z.; Liu, D. R. (2018). "Evolved Cas9 Variants with Broad PAM Compatibility and High DNA Specificity". Nature. 556 (7699): 57–63. PMID 29512652.
- Maianti, J. P.; McFedries, A.; Foda, Z. H.; Kleiner, R. E.; Du, X.-Q.; Leissring, M. A.; Tang, W.-J.; Charron, M. J.; Seeliger, M. A.; Saghatelian, A.; Liu, D. R. Nature 511, 94-98 (2014). “Anti-Diabetic Activity of Insulin-Degrading Enzyme Inhibitors Mediated by Multiple Hormones” PMC4142213
- Anzalone, A.V.; Randolph, P.B.; Davis, J.R.; Sousa, A.A.; Koblan, L.W.; Levy, J.M.; Chen, P.J.; Wilson, C.; Newby, G.A.; Raguram, A.; Liu, D.R. Nature, 576, 149–157 (2019). “Search-and-replace genome editing without double-strand breaks or donor DNA.” PMCID: PMC6907074
- Mok, B. Y; de Moraes, M. H; Zeng, J; Bosch, D. E; Kotrys, A. V; Raguram, A.; Hsu, F; Radey, M.C; Broko Peterson, B; Mootha, V.K; Mougous, J.D; Liu, D. R. Nature. available online (2020). "An interbacterial cytidine deaminase toxin enables mitochondrial base editing." PMCID: PMC7381381
See also
- DNA‐Templated Organic Synthesis
References
- ^ a b "David R. Liu". Liu Group. 2018-10-22. Retrieved 2019-04-02.
- ^ a b c "Asian American: David Liu Speeds Up Evolution of Therapeutic Proteins". Goldsea Asian American Business: Asian Media Group. April 18, 2011.
- ^ Yang, Sophia (December 19, 2017). "Taiwanese-American named scientist of the yea... | Taiwan News". Taiwan News.
- ^ "Science Talent Search 1990". Society for Science. Retrieved 2023-04-18.
- ^ Bradt, Steve (2 June 2005). "Chemist, card shark Liu takes off". Harvard Gazette.
- ^ "CV". Google Docs. Retrieved 8 June 2021.
- ^ "David R. Liu". chemistry.harvard.edu. Retrieved 2019-04-02.
- ^ "David R. Liu, PhD Bio". HHMI. Archived from the original on 18 February 2013. Retrieved 29 December 2017. [verification needed]
- ^ Citation error. See inline comment how to fix. [verification needed]
- ^ Liu, David R. (23 April 2019), Can we cure genetic diseases by rewriting DNA?, retrieved 2019-04-25
- ^ "News from the National Academy of Sciences". April 26, 2021. Retrieved July 4, 2021.
Newly elected members and their affiliations at the time of election are: … Liu, David R.; investigator, Howard Hughes Medical Institute; and Thomas Dudley Cabot Professor of the Natural Sciences, department of chemistry and chemical biology, Harvard University, Cambridge, Mass.
, entry in member directory:"Member Directory". National Academy of Sciences. Retrieved July 4, 2021. - ^ King Faisal Prize 2022
- PMID 27096365.
- PMID 29160308.
- PMID 31634902.
- PMID 19648931.
- PMID 23674678.
- PMID 30323312.
- ^ "David R. Liu". Google Scholar. Retrieved 13 December 2022.
- ^ Brian Gormley, "Flagship Ventures Hatches Two More Health-Care Companies", The Wall Street Journal (March 17, 2011)
- ^ Keown, Alex (November 22, 2017). "Cambridge's Ensemble Therapeutics Quietly Shuts Down After 13 Years". BioSpace.
- ^ https://news.harvard.edu/gazette/story/2005/06/chemist-card-shark-liu-takes-off/